INHALE THERAPEUTIC SYSTEMS INC
8-K, 1999-10-04
PHARMACEUTICAL PREPARATIONS
Previous: FIRST TRUST SPECIAL SITUATIONS TRUST SERIES 73, 497J, 1999-10-04
Next: URBAN SHOPPING CENTERS INC, 8-K, 1999-10-04



\<PAGE>

                     SECURITIES AND EXCHANGE COMMISSION

                            WASHINGTON, D.C. 20549

                                   FORM 8-K

                                CURRENT REPORT


                      Pursuant to Section 13 or 15(d) of
                     The Securities Exchange Act of 1934


                             September 29, 1999
             ------------------------------------------------
             Date of Report (Date of earliest event reported)


                      INHALE THERAPEUTIC SYSTEMS, INC.
          ------------------------------------------------------
          (Exact name of registrant as specified in its charter)


          Delaware                    023556              94-3134940
- ----------------------------  --------------------  --------------------------
(State or other jurisdiction       (Commission          (I.R.S. Employer
   of incorporation)               File Number)        Identification No.)


                              150 Industrial Road
                              San Carlos, CA 94070
                  ----------------------------------------
                  (Address of principal executive offices)


                                (650) 631-3100
             ----------------------------------------------------
             (Registrant's telephone number, including area code)

                         Inhale Therapeutic Systems
             ----------------------------------------------------
                (Former name, if changed since last report)


                                       1.

<PAGE>

ITEM 5.   OTHER EVENTS


     On September 29, 1999, Inhale Therapeutic Systems, Inc. announced its
intention to issue $100 million aggregate principal amount of convertible
subordinated debentures ($120 million if the over-allotment option is
exercised in full).  A press release relating to the issuance is attached
hereto as Exhibit 99.1.

ITEM 7.   FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS

          (c)  Exhibits

               99.1  Press Release dated September 29, 1999





                                       2.

<PAGE>

                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                INHALE THERAPEUTIC SYSTEMS, INC.



Dated: September 29, 1999       By: /s/ Brigid A. Makes
                                    ------------------------------------------
                                    Brigid A. Makes
                                    Chief Financial Officer and Vice President
                                    of Finance and Administration






                                       3.


<PAGE>

                                  EXHIBIT 99.1


                      INHALE ANNOUNCES PROPOSED ISSUANCE OF
                       CONVERTIBLE SUBORDINATED DEBENTURES

SAN CARLOS, CA, SEPTEMBER 29, 1999 -- Inhale Therapeutic Systems, Inc.
(Nasdaq:INHL) today announced that it intends to issue $100 million aggregate
principal amount of convertible subordinated debentures ($120 million if the
over-allotment option is exercised in full).  It intends to sell the
debentures in a private offering in the United States to qualified
institutional buyers under Rule 144A of the Securities Act of 1933, as
amended, and a limited number of accredited investors under Rule 501 of the
Securities Act. The debentures will be convertible into shares of Inhale's
common stock and will have a seven-year term.

The net proceeds of the offering will be used by Inhale to fund expansion of
its production capabilities and facilities, various product and technology
development programs, acquisitions, working capital and general corporate
purposes. The offering is subject to market conditions and other factors.

The debentures to be offered will not be registered under the Securities Act
or applicable state securities laws, and may not be offered or sold in the
United States absent registration under the Securities Act and applicable
state securities laws or available exemptions from the registration
requirements.

This release contains forward-looking statements that reflect management's
current views as to Inhale's collaborative arrangements, clinical trials,
product developments, manufacturing scale-up, and other future events and
operations. These forward-looking statements involve uncertainties and other
risks that are detailed in Inhale's reports and other filings with the SEC,
including its Form 10-Q for the fiscal quarter ended June 30, 1999. Actual
results could differ materially from these forward-looking statements.



                                       4.




© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission